ACTIVE, NOT RECRUITING
In this phase 2, single-arm, multi cohort trial, the safety and efficacy of tepotinib, an oral and once-daily MET inhibitor, was investigated in patients with advanced or metastatic NSCLC harboring MET alterations.1,2
The primary outcome of this trial was:
This trial also measured:
US Medical Information: 888-275-7376 - eMediUSA@emdserono.com
Global Communication Center: +49 6151 72 5200 - service@emdgroup.com
Singapore Medical Information: +65 6890 6638 - medinfo_singapore@merckgroup.com
_
*For a full list of all outcome measures and inclusion and exclusion criteria, please visit ClinicalTrials.gov NCT02864992.
†Actual enrollment.
‡500 mg tepotinib hydrochloride hydrate which is equivalent to 450 mg tepotinib (the free base form).
§Treatment continues until progression of disease, death, withdrawal of consent, or development of unacceptable toxicities.
DC, disease control; DOR, duration of response; HRQoL, health-related quality of life; OR, objective response; OS, overall survival; PFS, progression-free survival.
Tepotinib is being investigated in this clinical trial and is under clinical investigation in several countries. This page describes one of the clinical trials for tepotinib, and it includes information about how the safety and efficacy of tepotinib will be measured and evaluated. The safety and efficacy of tepotinib have to be investigated following the respective local regulations and laws. There is no guarantee that tepotinib will be approved in the sought-after indication by the competent health authority in your country.